Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSPI seeks fed block on Promensil ads, labels

This article was originally published in The Tan Sheet

Executive Summary

The Center for Science in the Public Interest asks FDA and the Federal Trade Commission to halt Natrol's advertising and health claims for its red clover dietary supplement Promensil, indicated for the treatment of hot flashes, night sweats and mood swings. In a Sept. 12 letter to the agencies, CSPI said Natrol's claims that Promensil is "the only supplement proven to reduce menopause symptoms" and that it promotes "heart health" are deceptive and misleading. CSPI says its own analysis of the scientific research to support the efficacy of the supplement showed the data did not support Natrol's claims. The letter requests the Chatsworth, Calif.-based firm reimburse consumers, pay a penalty and run corrective advertising to "set the record straight"...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel